Advances in Nuclear Medicine
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: 25 February 2025 | Viewed by 257
Special Issue Editor
Special Issue Information
Dear Colleagues,
We are pleased to invite authors to contribute to a Special Issue on "Advances in Nuclear Medicine" for publication in our esteemed journal. This Special Issue aims to provide a comprehensive platform for researchers, clinicians, and experts in the field to showcase the latest breakthroughs, innovations, and advancements in nuclear medicine. Nuclear medicine plays a pivotal role in diagnostic imaging, therapeutic interventions, and personalized medicine. This Special Issue will encompass a wide spectrum of topics, including but not limited to novel radiopharmaceuticals, imaging techniques, therapeutic applications, and technological developments. We encourage submissions of original research articles and reviews that contribute to the evolving landscape of nuclear medicine. Authors are invited to explore diverse areas within the field, such as the application of artificial intelligence in image analysis, advancements in hybrid imaging modalities, targeted radionuclide therapies, and emerging radiotracers. We also welcome submissions addressing challenges and opportunities in nuclear medicine, fostering interdisciplinary collaboration. This Special Issue provides an excellent opportunity for researchers and practitioners to disseminate their work, share insights, and contribute to the ongoing progress in nuclear medicine. Accepted articles will benefit from high visibility and exposure within the scientific community.
Prof. Dr. Sérgio Augusto Lopes De Souza
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- radiopharmaceuticals
- PET
- SPECT
- hybrid imaging modalities
- radionuclide therapies
- radiotracers
- imaging techniques
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
